$CELUW News
Last published 2w ago
- 2w agoCELUCELUWCelularity Regains Compliance with Nasdaq Periodic Reporting RequirementGlobeNewswireFLORHAM PARK, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, today announced that it received written
- 2mo agoCELUCELUWCelularity Provides Update Regarding Nasdaq Listing ComplianceGlobeNewswireFLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company") today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications
- 5mo agoCELUCELUWCelularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell TherapiesGlobeNewswireFLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular
- 5mo agoCELUCELUWCelularity Releases CEO Letter to ShareholdersGlobeNewswireFLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering
- 5mo agoCELUCELUWCelularity Appoints Rick Gonzalez as Chief Commercial OfficerGlobeNewswireFLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular
- 5mo agoCELUCELUWCelularity Receives Nasdaq Notice Regarding Form 10-QGlobeNewswireFLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a longevity-focused regenerative and cellular medicine company, today announced that it received a notification letter
- 6mo agoCELUCELUWCelularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic TransformationGlobeNewswireFLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company, today announced that it has filed its
- 6mo agoCELUCELUWCelularity Announces Closing of Transaction with NexGelGlobeNewswireFLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, today announced the closing of its previously
- 6mo agoCELUCELUWCelularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K FilingGlobeNewswireFLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a longevity-focused regenerative and cellular medicine company, today announced that on April 16, 2026, the Company
- 8mo agoCELUCELUWNXGLCelularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product OpportunitiesGlobeNewswireBiovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications.Three pipeline 510(k) medical
- 8mo agoCELUCELUWCelularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused StrategyGlobeNewswireTransaction expected to generate up to $35 million in upfront and milestone paymentsCelularity retains exclusive manufacturing rights, creating continued biomaterials revenue and margin opportunityOrganizational
- 9mo agoCELUCELUWCelularity Receives $12.2 Million from Sale of New Jersey Net Operating LossesGlobeNewswireFLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Million in net cash
- 10mo agoCELUCELUWCelularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage DeterminationsGlobeNewswireFLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments
- 10mo agoCELUCELUWCelularity Announces Closing of Financing TransactionsGlobeNewswireFLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the
- 10mo agoCELUCELUWCelularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic VisionGlobeNewswireThe contemplated financing transactions would provide up to $12 Million in capital to support Celularity's strategic priorities around longevity and preservation of human performance. FLORHAM PARK, N.J., Dec. 18, 2025
- 1y agoCELUCELUWCelularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye CareGlobeNewswireFLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company addressing age-related and degenerative diseases, announced today a
- 1y agoCELUCELUWCelularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery DiseaseGlobeNewswireFirst-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery diseaseCelularity PDA-002 achieved durable wound healing with just two intramuscular dosesAs a qualified stem cell therapy
- 1y agoCELUCELUWCelularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) ComplianceGlobeNewswireCompany on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan.Company
- 1y agoCELUCELUWCelularity Receives Nasdaq Notice Regarding Form 10-QGlobeNewswireFLORHAM PARK, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company focused on addressing age-related and degenerative
- 1y agoCELUCELUWCelularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured DebtGlobeNewswireRetired all principal and accrued interest owed its two senior secured lenders, Resorts World Inc. Pte. Ltd., or RWI, and C.V. Starr and Co., Inc., eliminating all senior secured debt from its balance sheet.Entered into
- 1y agoCELUCELUWCelularity Hails New Florida Law Opening Patient Access to Stem Cell TherapiesGlobeNewswireNew law goes into effect on July 1st authorizing Florida physicians to provide stem cell therapies to their patients for orthopedics, wound care, and pain management FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE)
- 1y agoCELUCELUWCelularity Announces Chief Financial Officer TransitionGlobeNewswireFLORHAM PARK, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that it terminated the employment of
- 1y agoCELUCELUWCelularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane TechnologyGlobeNewswireHighlights the unique potential of Celularity's proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstructionSupports broad range of regenerative medicine applications
- 1y agoCELUCELUWCelularity Receives Nasdaq Notice Regarding Form 10-QGlobeNewswireFLORHAM PARK, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a cellular and regenerative medicine company, today announced that on May 28, 2025, Nasdaq notified
- 1y agoCELUCELUWCelularity Announces Full Year 2024 Operating and Financial ResultsGlobeNewswireFLORHAM PARK, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced operating and financial results for the
- 1y agoCELUCELUWCelularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq FeesGlobeNewswireFLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a cellular and regenerative medicine company, today announced that Nasdaq has notified the Company
- 1y agoCELUCELUWCelularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes ProductsGlobeNewswireFLORHAM PARK, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, welcomes action by the Centers for Medicare &
- 1y agoCELUCELUWCelularity Announces Publication of "Senescence, NK cells, and cancer: navigating the crossroads of aging and disease" in the April 4, 2025, Issue of Frontiers in ImmunologyGlobeNewswireFLORHAM PARK, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced a key publication in the April 4,
- 1y agoCELUCELUWCelularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care ProductsGlobeNewswireFLORHAM PARK, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that on December 19, 2024, it received
- 1y agoCELUCELUWCelularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy CompanyGlobeNewswireFLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a cellular and regenerative medicine company, today announced that it has entered into a Master
- 1y agoCELUCELUWMASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDsGlobeNewswireFLORHAM PARK, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Celularity issues the following announcement on behalf of the members of the MASS Coalition: MASS Coalition Welcomes Trump Order Freezing Skin Substitute
- 1y agoCELUCELUWCelularity Inc. Announces Resolution of Nasdaq Listing Compliance MatterGlobeNewswireFLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that it has received a letter from the
- 1y agoCELUCELUWCelularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023GlobeNewswireCelularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024, and is now current with its quarterly report filings Reported Total Net Revenue for the Three Months and the Nine Months ending
- 1y agoCELUCELUWCelularity Inc. Announces Receipt of Nasdaq NotificationGlobeNewswireFLORHAM PARK, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced
- 1y agoCELUCELUWCelularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia PacificGlobeNewswireCelularity is collaborating with its strategic partner, Genting Berhad, to bring Celularity placenta-derived allogeneic stem cell therapeutics to the Asia Pacific regionGenting Berhad announced groundbreaking on a new,
- 1y agoCELUCELUWCelularity Inc. Announces Resolution of Nasdaq Listing Compliance MatterGlobeNewswireFLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, today announced that the Nasdaq Listing Qualifications Hearings Panel
- 2y agoCELUCELUWCelularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 MillionGlobeNewswireCelularity Raises Full Year 2024 Expected Net Sales Guidance to $54 Million to $60 Million, Compared to Previous Guidance of $50 Million to $56 MillionOctober Expected Net Sales of $8.3 Million to $8.9 Million Marks the
- 2y agoCELUCELUWCelularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings PanelGlobeNewswireFLORHAM PARK, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, today announced that it has requested a hearing before the Nasdaq
- 2y agoCELUCELUWCelularity Provides Corporate UpdateGlobeNewswireFLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri,
- 2y agoCELUCELUWCelularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an AppealGlobeNewswireFLORHAM PARK, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative medicine company developing and commercializing placental-derived technologies, today announced that
- 2y agoCELUCELUWCelularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.GlobeNewswireFLORHAM PARK, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, today announced that it had added to its commercial portfolio of
- 2y agoCELUCELUWCelularity to Present at H.C. Wainwright's 26th Annual Global Investment ConferenceGlobeNewswireFLORHAM PARK, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced
- 2y agoCELUCELUWCelularity Appoints Richard J. Berman to its Board of DirectorsGlobeNewswireFLORHAM PARK, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced
- 2y agoCELUCELUWCelularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingGlobeNewswireFLORHAM PARK, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced
- 2y agoCELUCELUWCelularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023GlobeNewswireFor the first quarter 2024, Celularity expects combined net sales of $14.8 million for its advanced biomaterial product and biobanking businesses, compared to the $10.25 million to $11.5 million guidance range previously
- 2y agoCELUCELUWCelularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireFLORHAM PARK, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced
- 2y agoCELUCELUWCelularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingGlobeNewswireFLORHAM PARK, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial
- 2y agoCELUCELUWCelularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T TherapyGlobeNewswireFLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced
- 2y agoCELUCELUWCelularity Inc. to Host Investor and Analyst Research & Development DayGlobeNewswireFLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced
- 2y agoCELUCELUWCelularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K FilingGlobeNewswireFLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial